Summit Therapeutics Inc. (NASDAQ: SMMT) AI-Powered Stock Analysis
See how Summit Therapeutics Inc. scores across key metrics like financial growth, valuation, and market position on the NASDAQ, using AI-driven evaluation.
SMMT●NASDAQ
HealthcareBiotechnology
$13.49
$0.45(3.42%)
U.S. Market is Open · 15:17
Summit Therapeutics Inc. (NASDAQ: SMMT) AI-Powered Stock Analysis
See how Summit Therapeutics Inc. scores across key metrics like financial growth, valuation, and market position on the NASDAQ, using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full DisclaimerSummit Therapeutics Inc. (NASDAQ: SMMT) Stock Overall Grade
Summit Therapeutics Inc.'s grade for its NASDAQ listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Summit Therapeutics Inc.'s overall NASDAQ stock rating.
Forecast
BScore
60/100Financial Growth
CScore
40/100Fundamental Growth
CScore
44/100Key Ratios
C+Score
55/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
99/100Analyst Consensus
BScore
67/100Summit Therapeutics Inc. (NASDAQ: SMMT) AI-Powered Stock Analysis
On the NASDAQ, SMMT demonstrates Good performance with an overall Forecast Score of 60/100 (B), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (44/100, C) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (99/100, A+), the NASDAQ-listed stock shows competitive strength. Analyst Consensus (67/100, B) suggests High divergence in outlook.(NASDAQ: SMMT) Component Analysis Explained
Understand the key factors behind each Summit Therapeutics Inc. (NASDAQ: SMMT) stock grade, including financials, comparisons, and forecasts.